News
The global healthcare industry is transforming—quickly transitioning from proprietary solutions to a foundation of open, global GS1 standards.
Travagliato (Brescia), 3 June 2021 – Antares Vision Group, the international leader in the pharmaceutical sector for track & trace hardware and software solutions (anti-counterfeiting and supply chain transparency), with an established presence in inspection systems (quality control), and active in smart data management (production efficiency and end-to-end supply chain digitalization, from raw materials to the final consumer), announced today that its subsidiary rfXcel has successfully implemented an end-to-end traceability hub to monitor and secure the Kingdom of Bahrain’s global pharmaceutical supply chain process. The initial value of this contract is around 4-6% of Antares Vision FY 2020 Pro-forma revenues.
Bahrain’s National Health Regulatory Authority (NHRA) and Supreme Council of Health selected Medical Value Chain, “MVC” and its partner rfXcel to provide the first GS1-compliant system to track its entire pharmaceutical supply chain on a blockchain platform. The end-to-end traceability hub delivers complete visibility into every node of the Kingdom’s supply chain, from the manufacturer of origin, importers, wholesalers, and distributors to pharmacies, clinics, and hospitals - all the way to individual patients.
The objective of the NHRA Bahrain Traceability Hub is to achieve the following:
- End-to-end traceability for all medicine imports to Bahrain
- Bahrain pharma supply chain to meet the global track & trace requirements and GS1 Standards
- Complete visibility and repository of medicine inventory & supply-chain info from manufacturers to agents/importers to wholesalers/distributors to pharmacies/hospitals and to patients/consumers
- Increase patient safety
- Detect and stop counterfeit medicines
- Analytics of medicine imports and consumptions in Bahrain
- Manage product recalls and shortages efficiently and timely
Glenn Abood, rfXcel CEO, said: “The end-to-end traceability hub offers an array of other benefits for all pharmaceutical supply chain stakeholders. The hub is the first of its kind in the Gulf Cooperation Council. It creates a single source of truth for all medications, which means improved patient safety, better flow of information, and more accurate inventory management. It is also a powerful tool to prevent counterfeit and substandard drugs from reaching the market”.
Emidio Zorzella, Antares Vision Group CEO, said: “I am honoured that the Kingdom of Bahrain chose Antares Vision Group in partnership with MVC to secure and optimize its pharma supply chain. In the near future, we expect to announce national traceability hubs in other countries to track pharmaceutical, agricultural and consumer products”
MVC President Leo Giacometto said, “When we set up our company to provide a blockchain-enabled track and trace platform to provide customs clearances and supply chain financing, we needed the absolute best Track and Trace solution and most experienced team in the market; that is rfXcel, now part of Antares Vision Group!”
ABOUT ANTARES VISION GROUP
Listed since April 2019 on the Italian Stock Exchange in the AIM Market, and from 14 May 2021 on Mercato Telematico Azionario (MTA) STAR segment, the Antares Vision Group guarantees protection of products, people and brands through inspection systems for quality control, Track & Trace solutions for anti-counterfeiting and supply chain transparency, smart data management tools for maximized efficiency and digitalization of the supply chain, from raw materials to the final consumer. The Antares Vision Group is active in the pharmaceutical market and in Life Science in general (biomedical devices and hospitals), in beverage, food, cosmetic and in consumer-packaged goods. The Group reaches over 60 countries in the world with complete and flexible solutions, hardware, and software, with related services and counts 7 production facilities in Italy (Brescia, Parma, Piacenza, Latina, Padua and Vicenza), 22 foreign subsidiaries (Germany [2], France [2], USA [5], Brazil [2], United Kingdom [2], India, Russia [3], Hong Kong, China, Ireland, Croatia and Serbia), 3 Innovation and Research Centers (Italy) and a worldwide network of more than 40 partners. Thanks to the twenty years of experience in vision technologies of the two founding partners, the Antares Vision Group is the supplier of 10 out of 20 leading pharmaceutical companies in the world, with more than 25.000 inspection systems, that ensure everyday product safety and quality, 6.500 quality controls and more than 3.500 serialization modules on lines installed all over the. With the aim of continuing and supporting the growth and development strategy, during 2019 participation agreements were finalized with T2 Software, a Brazilian company specialized in smart data management solutions, and Orobix, an Italian company leader in artificial intelligence services, as well as the acquisition of 100% of FT System, the leader in control and inspection in the beverage sector. In 2020, Antares Vision acquired 82.83% of Tradeticity, a Croatian company specialized in software management of traceability and serialization processes, 100% of Convel, an Italian company specialized in automated inspection machines for the pharmaceutical industry, the assets of Adents High Tech International, a French company specialized in software for serialization and traceability, 100% of Applied Vision, a global leader in inspection systems for glass and metal containers in food & beverage. In March 2021, Antares Vision acquired 100% of rfXcel Corporation, specialized in software solutions for digitalization and supply chain transparency based in the U.S., and 100% of Pen-Tec and Tecnel, through FT System, increasing specialization in Food & Beverage inspection sector. In 2019 Emidio Zorzella and Massimo Bonardi won the Ernst & Young “Entrepreneur of the Year” award for innovation.
For further information
Antares Vision S.p.A.
Via del Ferro, n. 16
25039 – Travagliato (BS)
Alessandro Baj Badino (Investor Relator)
Tel.: +39 030 72 83 500
E-mail: investors@antaresvision.com
IR ADVISOR
IR Top Consulting
Via Bigli, n. 19
20121 – Milano
Tel.: +39 02 45473884
Maria Antonietta Pireddu
E-mail: m.pireddu@irtop.com
Antonio Buozzi
E-mail: a.buozzi@irtop.com
Since 2015, medical device manufacturers have been scrambling to ensure they are successfully complying with various governments’ rules, regulations and timelines for Unique Device Identification (UDI). Moreover, they often use multiple systems to do so, and as a result, duplicate efforts instead of boosting efficiencies!
Different rules in different countries pose unique challenges to medical device companies. Meanwhile, more and more agencies will be implementing new rules over the next 5 years—and manufacturers often find themselves feeling in the dark with what these requirements are and how regulators want to receive them.
While the industry has achieved many milestones, there are a lot of unanswered questions in the healthcare realm. Join us for a compelling webinar where you will learn the answers to:
- How are companies successfully creating, updating and sharing UDI data?
- What systems, processes and tools are helping manufacturers satisfy individual data needs of both regulators and customers?
- Where can people go to get educated, find best practices and drive efficiencies?
Speakers: Jason Gunn and Mike Crabb
When: Thursday, March 25 at 11 am CET
Did you ever want to learn how GS1 Member Organisations provide healthcare data connectors to Healthcare regulatory and commercial authorities? How global healthcare purchasing organizations, hospitals use data models to receive data from datapools? This is your chance! This is the time to learn to show your members direct value.
In this short but intense session, you will discover...
- Latest developments in healthcare,
- Important aspects to consider about data models in healthcare,
- How to connect easily to UDI regulatory databases (e.g. GUDID, EUDAMED, etc.)
- How to use GDSN and healthcare connectors.
We open the floor for you to ask our experts all your burning questions!
When: February 24th at 12:00 pm (UTC-5 time)
You want to attend but have calendar conflicts? Register anyway, and we will send you the webinar recording after the meeting.
The deadline for implementation of traceability solutions for Medical Devices and In-vitro Devices is just around the corner. However, the MDR and IVDR regulations raise certain questions and challenges for manufacturers, importers, and authorized representatives.
SoftGroup and GS1 Bulgaria have teamed up to provide a compact and understandable overview of the most important regulatory updates as well as the specific UDI requirements.
When: 26th November 2020, at 10 a.m. EEST
Governments, regulators, hospitals and retail pharmacies in more than 70 countries are driving implementation of GS1 standards in healthcare and many of the implementations require solution providers to support GS1 standards in their systems and processes to provide appropriate solutions to their customers.
GS1 Healthcare will soon give the access on its Solution Partners webpage to an interactive map which will display all our Solution Partners per country.